Non-coding recurrent mutations in chronic lymphocytic leukaemia
Author(s) -
Xosé S. Puente,
Sı́lvia Beà,
Rafael Valdés-Mas,
Neus Villamor,
Jesús GutiérrezAbril,
José I. MartínSubero,
Marta Munar,
Carlota Rubio-Pérez,
Pedro Jares,
Marta Aymerich,
Tycho Baumann,
Renée Beekman,
Laura Belver,
Ana Carrió,
Giancarlo Castellano,
Guillem Clot,
Enrique Colado,
Dolors Colomer,
Dolors Costa,
Julio Delgado,
Anna Enjuanes,
Xavier Estivill,
Adolfo A. Ferrando,
Josep Lluís Gelpí,
Blanca González,
Santiago González,
Marcos González,
Marta Gut,
Jesús M. Hernández-Rivas,
Mònica LópezGuerra,
David MartínGarcia,
Alba Navarro,
Pilar Nicolás,
Modesto Orozco,
Ángel Ramírez Payer,
Magda Pinyol,
David G. Pisano,
Diana Puente,
Ana C. Queirós,
Vı́ctor Quesada,
Carlos Romeo-Casabona,
Cristina Royo,
Romina Royo,
Marı́a Rozman,
Núria Russiñol,
Itziar Salaverría,
Kostas Stamatopoulos,
Hendrik G. Stunnenberg,
David Tamborero,
María José Terol,
Alfonso Valencia,
Núria LópezBigas,
David Torrents,
Ivo Gut,
Armando LópezGuillermo,
Carlos LópezOtín,
Elı́as Campo
Publication year - 2015
Publication title -
nature
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 15.993
H-Index - 1226
eISSN - 1476-4687
pISSN - 0028-0836
DOI - 10.1038/nature14666
Subject(s) - chronic lymphocytic leukemia , enhancer , lymphocytosis , cancer research , biology , exon , genetics , gene , leukemia , immunology , transcription factor
Chronic lymphocytic leukaemia (CLL) is a frequent disease in which the genetic alterations determining the clinicobiological behaviour are not fully understood. Here we describe a comprehensive evaluation of the genomic landscape of 452 CLL cases and 54 patients with monoclonal B-lymphocytosis, a precursor disorder. We extend the number of CLL driver alterations, including changes in ZNF292, ZMYM3, ARID1A and PTPN11. We also identify novel recurrent mutations in non-coding regions, including the 3' region of NOTCH1, which cause aberrant splicing events, increase NOTCH1 activity and result in a more aggressive disease. In addition, mutations in an enhancer located on chromosome 9p13 result in reduced expression of the B-cell-specific transcription factor PAX5. The accumulative number of driver alterations (0 to ≥4) discriminated between patients with differences in clinical behaviour. This study provides an integrated portrait of the CLL genomic landscape, identifies new recurrent driver mutations of the disease, and suggests clinical interventions that may improve the management of this neoplasia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom